ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 775.1 USD | -1.52% |
|
+0.42% | +32.91% |
| 04:53pm | Eli Lilly: research collaboration with Totus Medicines | CF |
| 04:25pm | Eli Lilly: positive trials in type 2 diabetes | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
787
USD
Average target price
850.4
USD
Spread / Average Target
+8.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.91% | 71TCr | |
| +30.77% | 60TCr | |
| -1.89% | 37TCr | |
| +20.18% | 33TCr | |
| +5.86% | 29TCr | |
| +14.77% | 24TCr | |
| +9.13% | 21TCr | |
| -3.97% | 20TCr | |
| +9.04% | 17TCr | |
| +0.37% | 16TCr |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly's $14 Million Insulin Settlement Shelved Amid Unfavorable Ruling